Skip to main content
Premium Trial:

Request an Annual Quote

TheraGenetics Lands $6M in Series A VC Funds

NEW YORK (GenomeWeb News) — TheraGenetics has raised $6 million in a Series A round of venture capital financing, the company said Tuesday.  
 
TheraGenetics CEO Richard Kivel said the funds will help expand the company’s IP position and will speed its diagnostic development.
 
The company has developed a series of diagnostics for disorders affecting the central nervous system such as schizophrenia, Alzheimer’s disease, and mood disorders.
 
Swarraton Partners led the round, which included funds from Tudor Capital, IP Group, and IP Venture Fund, which is IP Group's venture capital fund that was raised in partnership with the European Investment Fund.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.